Elevated GLCE levels in BPH (49% of the patients) and prostate cancer (21% of the patients) could indicate a disruption of the restricting mechanism(s) and a specific type of GLCE expression disorganization in this pathology, while a decrease in GLCE expression may be associated with specific prostate cancer subtypes. Here, GLCE is linked to prostate carcinoma.